As Eisai, Biogen plot a course to accelerated approvals for Alzheimer’s drug, a mob of skeptics are waiting to decipher hard numbers

Welcome to the big catalyst of Q3.

Eisai and Biogen won’t reveal their data from a mid-stage study of BAN2401 in Alzheimer’s disease until tomorrow, but there’s no question that they’re presenting this as a major breakthrough in the field that needs to be hustled to patients as rapidly as possible.